@elizabethcairns looks at the problem with Her2-low testing.
https://www.evaluate.com/vantage/articles/analysis/spotlight/problem-her2-low-testing
"#Daiichi and #Astrazeneca want to extend #Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work."